AVADEL PHARMACEUTICALS PLC's ticker is AVDL and the CUSIP is 05337M104. A total of 84 filers reported holding AVADEL PHARMACEUTICALS PLC in Q2 2021. The put-call ratio across all filers is 0.52 and the average weighting 0.1%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q3 2023 | $46,483,529 | -37.8% | 4,512,964 | -0.5% | 0.34% | -8.8% |
| Q2 2023 | $74,735,498 | +78.4% | 4,534,921 | -0.8% | 0.38% | +38.6% |
| Q1 2023 | $41,884,008 | +108.0% | 4,572,490 | +62.6% | 0.27% | +68.9% |
| Q4 2022 | $20,137,428 | +42.9% | 2,812,490 | 0.0% | 0.16% | +78.9% |
| Q3 2022 | $14,091,000 | +105.3% | 2,812,490 | 0.0% | 0.09% | +125.0% |
| Q2 2022 | $6,862,000 | -68.6% | 2,812,490 | -12.1% | 0.04% | -59.6% |
| Q1 2022 | $21,850,000 | -3.2% | 3,199,152 | +14.5% | 0.10% | +16.5% |
| Q4 2021 | $22,581,000 | -17.6% | 2,794,673 | 0.0% | 0.08% | -24.1% |
| Q3 2021 | $27,388,000 | +45.6% | 2,794,673 | 0.0% | 0.11% | +36.6% |
| Q2 2021 | $18,808,000 | -25.6% | 2,794,673 | 0.0% | 0.08% | -47.4% |
| Q1 2021 | $25,264,000 | +24.9% | 2,794,673 | -7.7% | 0.16% | +26.8% |
| Q4 2020 | $20,225,000 | – | 3,027,705 | – | 0.12% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| Stonepine Capital Management, LLC | 985,210 | $10,345,000 | 6.10% |
| Broadfin Capital, LLC | 3,568,122 | $37,465,000 | 5.54% |
| JW Asset Management, LLC | 444,439 | $4,667,000 | 3.42% |
| ARMISTICE CAPITAL, LLC | 1,688,000 | $17,724,000 | 2.09% |
| DEERFIELD MANAGEMENT COMPANY, L.P. (SERIES C) | 3,655,494 | $38,383,000 | 1.73% |
| FALCON POINT CAPITAL, LLC | 661,490 | $6,284,000 | 0.91% |
| KNOTT DAVID M | 158,555 | $1,665,000 | 0.71% |
| Perceptive Advisors | 3,098,010 | $32,530,000 | 0.62% |
| Sio Capital Management, LLC | 91,413 | $960,000 | 0.50% |
| HEARTLAND ADVISORS INC | 700,000 | $7,350,000 | 0.48% |